Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TXSVN Vaccine in Multiple Myeloma
NCT03762291Phase 1Completed
- Sponsor
- Baylor College of Medicine
- Start
- Aug 2021
- Primary completion
- Mar 2022
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CVD908ssb-TXSVN in multiple myeloma (MM), sponsored by Baylor College of Medicine. Primary endpoint: Dose Limiting Toxicity at 8 weeks. Started Aug 2021; status: completed.
02
Drugs
CVD908ssb-TXSVN
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03762291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03762291.